REDWOOD CITY, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Genitope Corporation today announced the appointment of two new members to the company's management team. Michael Buckley, Ph.D. joins as vice president of manufacturing, and Steven Chamow, Ph.D., will be Genitope's vice president of process sciences.
"As Genitope evolves from a late-stage drug development company, Mike and Steve bring us essential experience in biotechnology operations," said Dan W. Denney Jr., Ph.D., chairman and chief executive officer of Genitope Corporation. "Mike's expertise gained building and running the manufacturing operations for the commercialization of Bexxar(R) and Steve's real-world knowledge in creating manufacturing processes that meet regulatory requirements for novel cancer therapeutics will be extremely valuable as we move forward to become a world-class commercial enterprise."
Dr. Buckley has more than 18 years' experience in the biotechnology development and manufacturing sectors for both clinical candidates and commercially approved products. He joins Genitope Corporation after nine years at Corixa Corporation, formerly Coulter Pharmaceutical Inc. At Corixa, he held a number of operations and development positions, including vice president of manufacturing operations for Bexxar(R), a radioimmunotherapy compound for the treatment of non-Hodgkin's lymphoma. Previously, Dr. Buckley served as senior scientist of the Monoclonal Antibody Department at BioTransplant Inc. He received his Ph.D. in cellular immunology from the University of Medicine and Dentistry of New Jersey-Graduate School of Biomedical Sciences and his B.A. from the College of Wooster.
Dr. Chamow, who has more than 17 years' experience in the biopharmaceutical industry, joins Genitope from Abgenix Inc., where he served as vice president of process sciences and led the development of manufacturing processes that supported two investigational new drug applications. Prior to that, Dr. Chamow served as director in the Department of Biopharmaceutical Development at Scios Inc., where he was responsible for all process development and clinical manufacturing of the company's protein biotherapeutics. Dr. Chamow previously served as senior scientist in the Department of Recovery Sciences at Genentech Inc. Dr. Chamow holds a Ph.D. from the University of California, Davis and a B.A. from the University of California, Santa Cruz.
About Genitope Corporation
Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) Personalized Immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. Genitope Corporation is conducting a pivotal phase 3 trial using MyVax(R) Personalized Immunotherapy in previously untreated follicular non-Hodgkin's lymphoma patients. Genitope Corporation is based in Redwood City, California.
Forward Looking Statements
This news release contains "forward-looking statements." For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Genitope Corporation's results to differ materially from those indicated by these forward-looking statements, including without limitation, economic conditions, the Company's need for additional financing, intense competition in various aspects of its business, the risks of growth, its dependence on key personnel, pending litigation and other risks detailed in Genitope Corporation's filings with the Securities and Exchange Commission, including the Quarterly Report for the fiscal quarter ended September 30, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genitope Corporation undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Chief Financial Officer